FDA Greenlights Withdrawal of ALS Drug RELYVRIO Packets
Published Date: 8/29/2025
Notice
Summary
Amylyx Pharmaceuticals asked the FDA to take back its approval for the drug RELYVRIO, used in 1g and 3g packets. This means RELYVRIO won’t be available as an FDA-approved treatment anymore. Patients and healthcare providers should watch for updates on how this change might affect treatment options and costs.
Analyzed Economic Effects
1 provisions identified: 0 benefits, 1 costs, 0 mixed.
RELYVRIO FDA Approval Withdrawn
If you take RELYVRIO, the FDA approval for RELYVRIO (sodium phenylbutyrate and taurursodiol) in 3 gram and 1 gram packets has been withdrawn at the drugmaker Amylyx Pharmaceuticals' request. This means RELYVRIO will no longer be an FDA-approved treatment; patients and healthcare providers should watch for updates about how this change might affect treatment options and costs.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Take It Personal
Get Your Personalized Policy View
Start a Free Government Policy Watch to see how policy affects your household, then upgrade to PRIA Full Coverage for year-round monitoring.
Already have an account? Sign in